Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 8, 2012

View Archived Issues

Intellect Neurosciences and iNovacia enter research service agreement

Circassia begins phase III ToleroMune trial in cat allergy

Empagliflozin has beneficial effects on blood pressure

U.S. Navy to investigate Oxygen Biotherapeutics' Oxycyte wound therapy

Updated study results on orteronel in prostate cancer presented

Preclinical profile of the prostate cancer vaccine candidate AEZS-120

Mirabegron safe in male patients with bladder outlet obstruction

Patient recruitment completed in two phase III Afrezza trials

Deciphera Pharmaceuticals announces transition to oncology drug development

National Institute of Biomedical Innovation patents new antibodies for cancer

Allergan presents new FPRL1 receptor ligands

Novel agents for diabetes prepared by Danish group

Industrial Research and University of Liverpool disclose novel BACE1 inhibitors

Locus Pharmaceuticals patents new ITK inhibitors

Researchers in Thailand synthesize novel dihydrofolate reductase inhibitors

DVS-603 improves psoriasis symptoms

Takeda aims to expand vaccine pipeline with acquisition

Chugai files application for approval of Avastin in additional indication in Japan

XenoPort discloses encouraging results from phase I trial of fumaric acid ester compound

MAA for ceftobiprole in pneumonia accepted for review under E.U. decentralized procedure

NICE publishes new draft guidance on ranibizumab for DME

The Medicines Company voluntarily discontinues development of MDCO-2010

Cempra reports topline results from phase II trial in urogenital gonorrhea

EMA accepts masitinib MAA for review

Zeria discontinues development of product candidate for allergic rhinitis

4-Antibody receives additional milestone payments from HGS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
FDA greenlights Medtronic Onyx subdural hematoma treatment
BioWorld MedTech
Sometimes the darkest products (names) bring a bright spot of news to their developers, as the U.S. FDA clearance for Galway, Ireland-based Medtronic plc's Onyx...